Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00186186
Other study ID # 79130
Secondary ID
Status Completed
Phase Phase 4
First received September 13, 2005
Last updated December 11, 2012
Start date January 2004
Est. completion date January 2009

Study information

Verified date December 2012
Source Stanford University
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to examine the safety and efficacy of Depakote ER in bipolar depression and to evaluate metabolic and GABA changes with Depakote ER administration using PET and MRI/MRS brain imaging techniques.


Description:

Mood disorders are important public health problems. Bipolar disorder is a major psychiatric disorder characterized by mood cycles alternating between mania and depression and affects approximately 1% of the population. Most patients are treated beginning in the early twenties and then embark on a course marked by multiple recurrences, hospitalizations, and encounters with legal authorities. These disorders inflict substantial morbidity which yields important deficits in occupational and interpersonal function. The risk of suicide in mood disorders may be as high as 10%.

Although the outlook for recovery from acute manic or depressive episodes is generally excellent, the long-term prognosis of the disorder varies tremendously across the patient population. The introduction of lithium, anticonvulsants and atypical antipsychotics significantly changes the outlook for bipolar disorder, with some individuals on chronic treatment attaining complete remission and indefinite prophylaxis against mood episodes. However, such optimum outcomes may be limited to as few as one-third to one-half of all treated patients. The remaining experiences various combinations of breakthrough mood episodes, including chronic mood instability, persistent depression, and rapid cycling.

Very little research has been conducted with bipolar disorder, and no medications have an FDA indication to treat bipolar depression. Previous studies suggest that Depakote is promising in the treatment of mixed and depressed episodes of bipolar disorder. This study utilizes the extended release formulation of divalproex sodium, with demonstrated increased tolerability.

We propose investigating safety, tolerability and efficacy of Depakote ER monotherapy in Bipolar I, II or NOS depression, and monitoring associated changes in brain GABA levels. In addition, we intend to evaluate and assess the differences between brain metabolic rate and GABA levels in bipolar disorder patients and healthy volunteers.


Recruitment information / eligibility

Status Completed
Enrollment 28
Est. completion date January 2009
Est. primary completion date January 2009
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Bipolar I, II or NOS currently suffering from depression

- Both: both female and male participants are being studied

- Adults 18 years and older of any race

Exclusion Criteria:

- Schizophrenia or schizoaffective disorder and other disorders excluded at the discretion of the investigator's discretion

- Substance dependence within the past 3 months and abuse within the past 2 weeks prior to study.

- Positive screen for psychoactive drugs, stimulants or drugs of abuse (excluding marijuana, as long as dependence and abuse are ruled out according to DSM-IV)

- Significant risk harm to self or others based on history and mental status exam

- Clinically significant or unstable medical condition

- Unstable thyroid pathology and treatment initiated or altered within the past 3 months

- Clinically significant abnormal laboratory test results, vital signs, as judged by the investigators

- Women pregnant or nursing, or WOCBP who do not use adequate contraception or who are judged to be unreliable in their use of contraception

- Subjects who failed (because of inefficacy or adverse effects) an adequate trial of Depakote; eligible patient's may not have received Depakote within 30 days of screen

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
Depakote ER
Depakote ER

Locations

Country Name City State
United States Stanford University Bipolar Disorders Clinic Stanford California

Sponsors (3)

Lead Sponsor Collaborator
Stanford University Abbott, National Alliance for Research on Schizophrenia and Depression

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Montgomery Asberg Depression Rating Scale (MADRS) Change from baseline to endpoint in Montgomery Asberg Depression Rating Scale (MADRS) 7 weeks No
See also
  Status Clinical Trial Phase
Completed NCT04469322 - Pharmacogenetic Implementation Trial in Veterans With Treatment Refractory Depression N/A
Not yet recruiting NCT05958940 - BioClock: Bright Light Therapy for Depressive Disorders N/A
Recruiting NCT02919280 - Dallas 2K: A Natural History Study of Depression
Completed NCT00060489 - Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients With Bipolar Depression Phase 3
Recruiting NCT05767073 - LIVES: Personalized Lifestyle Intervention for Patients With Depression N/A
Completed NCT04121091 - Pramipexole to Target "Anhedonic Depression" Phase 2
Recruiting NCT04057378 - Optimal Electrical Stimulus During Electroconvulsive Therapy Phase 4
Completed NCT03287037 - The Effects of tDCS on Depressive Symptoms,Neurocognitive Function and HRV in Unipolar Depression and Bipolar Depression N/A
Completed NCT00483548 - Adjunctive Ziprasidone in the Treatment of Bipolar I Depression Phase 3
Not yet recruiting NCT05568823 - Biomarkers of ANTidepressant RESponse and Development Risk of Bipolar Disorder N/A
Completed NCT00191399 - Bipolar Depression Study: Bipolar Depression Assessment Study on Treatment Response Phase 4
Recruiting NCT05436613 - Transcranial Direct Current Stimulation Therapy for Bipolar Depression N/A
Completed NCT03538275 - Chronobiology and Depression: Circadian Analytics as a Biomarker for Depressive Subtypes
Recruiting NCT04846010 - Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2 Phase 1/Phase 2
Withdrawn NCT02625779 - Combined Cytidine and Creatine-containing Drug in the Treatment of the Bipolar Depression Phase 2
Not yet recruiting NCT06462196 - Natural History of Depression, Bipolar Disorder and Suicide Risk
Recruiting NCT02778256 - Study of the Effectiveness of Vestibular Stimulation Treatment in the Depressive Phase of Bipolar Disorder N/A
Active, not recruiting NCT04643210 - Management of my Bipolarity Intervention in Bipolar Disorder Patients N/A
Completed NCT01396447 - Safety, Tolerability, and Efficacy of Cariprazine in Participants With Bipolar Depression Phase 2
Enrolling by invitation NCT02827045 - Study of a Vestibular Biomarker of Phase in Bipolar Disorder